U2Bio Co., Ltd.

A221800

KR7221800006

Healthcare Facilities & Services

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
4,400 ^KRW	+5.52%		+7.06%	-16.67%

2023	U2Bio Co., Ltd. has filed an IPO.	CI
2020	Chang Moo Jeon acquired 8.5% stake in U2Bio CO. LTD. from MAC Fund, L.P. (Class B), a fund managed by M-Venture Investment, Inc. for KRW 1.6 billion.	CI

U2Bio CO. LTD. announced that it has received KRW 7 billion in funding

April 17, 2019

On April 18, 2019, U2Bio CO. LTD. (XKON:A221800) closed the transaction.

Latest news about U2Bio Co., Ltd.

U2Bio Co., Ltd. has filed an IPO.	23-04-12	CI
Chang Moo Jeon acquired 8.5% stake in U2Bio CO. LTD. from MAC Fund, L.P. (Class B), a fund managed by M-Venture Investment, Inc. for KRW 1.6 billion.	20-09-23	CI
U2Bio CO. LTD. announced that it has received KRW 7 billion in funding	19-04-17	CI
U2Bio CO. LTD. announced that it expects to receive KRW 7 billion in funding	19-04-11	CI
NDS Corporation acquired additional 11.9% stake in U2Bio CO. LTD. from BSK Potential Fund 1, fund of BSK Investment for KRW 3.8 billion.	18-10-05	CI
NDS Corporation acquired 11.85% stake in U2Bio CO. LTD. for KRW 3.8 billion.	18-10-04	CI
An undisclosed buyer acquired 5.26% stake in U2Bio CO. LTD. from CKD Venture Fund 4 managed by CKD Venture Capital Co., Ltd. for KRW 1.1 billion.	17-07-11	CI
U2Bio CO. LTD. announced that it has received KRW 1.5 billion in funding	16-08-09	CI
U2Bio CO. LTD. announced that it expects to receive KRW 1.5 billion in funding	16-08-08	CI

U2BIO CO., LTD. is a Korea-based company mainly engaged in the provision of diagnostic testing services. The Company is involved in the provision of the general diagnostic testing services, molecular diagnostic testing services, as well as medical information technology (IT) services. The general diagnostic testing services include the provision of diagnosis and inspection information such as immunological serology, hematology, urine and microbiology, and pathology excluding molecular diagnostics among in vitro diagnostic tests. The Molecular diagnostic testing services include the provision of diagnostic and testing information through tests such as urethritis, mastoiditis, vaginitis, and cervicitis. The medical IT services include the provision of customized medical services through software products.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
U2BIO CO., LTD.	-16.67%	36.36M
HCA HEALTHCARE, INC.	+16.49%	82.59B
CVS HEALTH CORPORATION	-29.52%	69.86B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	0.00%	26.5B
LABCORP HOLDINGS INC.	-13.29%	16.61B
FRESENIUS SE & CO. KGAA	+1.03%	17.29B
QUEST DIAGNOSTICS INCORPORATED	+1.57%	15.56B
NATERA, INC.	+71.63%	13.2B
REDE D'OR SÃO LUIZ S.A.	+1.53%	12.75B
TENET HEALTHCARE CORPORATION	+70.68%	12.6B

Other Healthcare Facilities & Services

U2Bio Co., Ltd.

Equities

A221800

KR7221800006

Healthcare Facilities & Services

U2Bio CO. LTD. announced that it has received KRW 7 billion in funding

Latest news about U2Bio Co., Ltd.

Chart U2Bio Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Healthcare Facilities & Services